Trial
NCT00991510
Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Collaborators
Parexel
Condition
Stable Renal Transplant Recipients
Intervention
mycophenolate mofetil (Myfenax)
Why stopped
Slow recruitment and lack of time to product launch
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-11-08